The Latest Breaking News from FDA

The FDA approved the first drug shown to slow down Alzheimer's. The Biden administration will send controversial cluster bombs to Ukraine. A study estimates PFAS is in nearly half of U.S. tap water.

The Food and Drug Administration (FDA) has approved the much awaited drug Leqembi which has been shown to slow the cognitive decline caused by Alzheimer’s, the most common type of dementia

Eisai and Biogen's Leqembi is the first drug to slow Alzheimer's progression to receive full FDA approval.

U.S. officials have granted full approval to a closely watched Alzheimer’s drug for patients with early stages of the disease

The first drug found to slow the progression of Alzheimer's disease has been granted full approval by the Food and Drug Administration.

The drug Leqembi targets plaque buildup in the brain, and it is approved for people in the early stages of the disease.

Health officials are endorsing two new vaccines against respiratory syncytial virus (RSV) for older Americans, alongside flu and Covid-19 vaccines, although there are uncertainties about the risks

With the growing prevalence of chronic conditions, an aging population, widespread adoption of digital technologies, and several R&D efforts, the pharmaceutical industry is poised for exponential growth and expansion. So, let’s compare leading pharma stocks AbbVie (ABBV) and Pfizer (PFE) to identify which is a better investment now. Keep reading….

FDA approves new test, which has been widely celebrated as a small victory in the fight to make childbirth safer in the US